AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Insulin-like growth factor 1 receptor including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Insulin-like growth factor 1 receptor therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Insulin-like growth factor 1 receptor, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Insulin-like growth factor 1 receptor. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Insulin-like growth factor 1 receptor. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Insulin-like growth factor 1 receptor includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Insulin-like growth factor 1 receptor
partner:
Reaxense
upacc:
P08069
UPID:
IGF1R_HUMAN
Alternative names:
Insulin-like growth factor I receptor
Alternative UPACC:
P08069; B1B5Y2; Q14CV2; Q9UCC0
Background:
The Insulin-like growth factor 1 receptor (IGF1R), a receptor tyrosine kinase, is pivotal in mediating the effects of IGF1. It binds IGF1 with high affinity, playing a crucial role in cell growth, survival, and tumor transformation. IGF1R's activation triggers multiple signaling pathways, including PI3K-AKT/PKB and Ras-MAPK, essential for cellular proliferation and inhibition of apoptosis.
Therapeutic significance:
IGF1R's involvement in Insulin-like growth factor 1 resistance, characterized by growth retardation and altered IGF1 levels, underscores its therapeutic potential. Targeting IGF1R could offer novel strategies for managing this disorder and possibly other malignancies reliant on IGF1R signaling.
